MHC class I antigens, immune surveillance, and tumor immune escape

Journal of Cellular Physiology

Volumn 195, Issue 3, 2003, Pages 346-355

  Garcia Lora, Angel ^a   Algarra, Ignacio ^b   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER CELL; CELL TRANSFORMATION; CLONE; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

ANIMALIA;

EID: 0038069515     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10290     Document Type: Review

References (89)

1. Abele R, Tampé R. 1999. Function of the transport complex TAP in cellular immune recognition. Biochim Biophys Acta 1461:405-419.
2. Abril E, Mendez RE, Garcia A, Serrano A, Cabrera T, Garrido F, Ruiz-Cabello F. 1996. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens 47:391-398.
3. Algarra I, Gaforio JJ, Garrido A, Mialdea MJ, Perez M, Garrido F. 1991. Heterogeneity of MHC-class I antigens in clones of methylcholanthrene induced tumors. Implications for local growth and metastasis. Int J Cancer 6:73-81.
4. 2microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520-524.
5. Bjorkman PJ, Parham P. 1990. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59:253-288.
6. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506-512.
7. Blanchet O, Bourge JF, Zinszner H, Tatari Z, Degos L, Paul P. 1991. DNA binding of regulatory factor interacting with MHC-class I gene enhancer correlates with MHC class I transcriptional level in class I defective cell lines. Int J Cancer 6:138-145.
8. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. 1994. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365.
9. Brady CS, Burt DJ, Bartholomew JS, Duggan-Keen MF, Glenville S, Telford N, Litlee AM, Davison J, Jimenez P, Ruiz-Cabello F, Garrido F, Stern PL. 2000. Multiple mechanism underlie HLA dysregulation in cervical cancer: Implications for immunotherapy. Tissue Antigens 55:401-411.
10. Braud VM, Allan DS, McMichael AJ. 1999. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 11(1):100-108.
11. Browning M, Petronzelli F, Bicknell D, Kraus P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W. 1996. Mechanism of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 47:364-371.
12. Burnet FM. 1970. The concept of immunological surveillance. Prog Exp Tumor Res 13:1-27.
13. Cabrera T, Sierra A, Fernandez MA, Herruzo A, Fabra A, Garrido F. 1996. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunol 50:127-134.
14. Cabrera T, Collado A, Fernandez MA, Ferron A, Sancho J, Ruiz- Cabello F, Garrido F. 1998. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 52: 114-123.
15. Cabrera T, Salinero J, Fernandez MA, Garrido A, Esquivias J, Garrido F. 2000. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Human Immunol 61:499-506.
16. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. 2003. The analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52(1):1-9.
17. Chen HL, Gabrilovich D, Virmani A, Ratnani I, Girgis KR, Nadaf- Rahrov S, Fernandez-Vina M, Carbone DP. 1996. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer 67:756-763.
18. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. 1997. The host-tumor immune conflict: From immunosuppression to resistance and destruction. Immunol Today 18:493-497.
19. Cromme FV, Airey J, Heemels MT, Ploegh HL, Ketaing PJ, Stern PL, Meijer CJLM, Walboomers JMM. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335-340.
20. 2 m gene expression. J Clin Invest 87:284-292.
21. Daar AS, Fuggle SV, Fabre JV, Ting A, Morris PJ. 1984. The detailed distribution of HLA ABC antigens in normal human organs. Transplantation 38:287-292.
22. Dovhey SE, Ghosh NS, Wright KL. 2000. Loss of interferon-γ inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res 60:5789-5796.
23. Ehrlich P. 1909. Ueber den jetzigen Stand der Karzinomforschung. (Title translation: About the current state of the art of cancer research). Ned Tijdschr Geneeskd 5(Pt1):273-290.
24. Engel AM, Svane IM, Rigaard J, Werdenlin O. 1997. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 45: 463-470.
25. Feenstra M, Veltkamp M, van Kuik J, Wiertsema S, Slootweg P, van den Tweel J, de Weger R, Tilanus M. 1999. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 54:235-425.
26. Fernandez JE, Concha A, Aranega A, Ruiz-Cabello F, Cabrera T, Garrido F. 1991. HLA class I and II expression in rhabdomyosarcomas. Immunobiology 182:440-448.
27. Ferrón A, Pérez-Ayala M, Concha A, Cabrera T, Redondo M, Oliva MR, Ruiz-Cabello F, Garrido F. 1989. MHC class I and II antigens on gastric carcinomas and autologous mucosa. J Immunogenet 16: 413-423.
28. Festenstein H, Garrido F. 1987. MHC antigens and malignancy. Nature 332:502-504.
29. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. 2001. Immunoselection by T lymphocytes generates repeated MHC class I deficient metastatic tumor variants. Int J Cancer 91:109-119.
30. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F. 2003. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer (in press).
31. Garrido F, Algarra I. 2001. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117-158.
32. Garrido F, Festenstein H, Schirrmacher V. 1976. Further evidence for derepression of H-2 and Ia like specificities of foreign haplotypes in mouse tumor cell lines. Nature 261:228-230.
33. Garrido A, Pérez M, Delgado C, Garrido ML, Rojano J, Algarra I, Garrido F. 1986. Influence of class I H-2 gene expression on local tumor growth. Exp Clin Imnunogenet 13:98-100.
34. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. 1993. Natural history of HLA expression during tumor development. Immunol Today 14:491-493.
35. Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar J, López-Botet M, Duggan-Keen M, Stern PL. 1997. Implications for immunosurveillance of altered class I phenotypes in humans tumors. Immunol Today 18:89-95.
36. Grandea AG, Van Kaer L. 2001. Tapasin: An ER chaperone that controls MHC class I assembly with peptide. Trends Immunol 22:194-199.
37. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363- 1366.
38. Hicklin DJ, Marincola FM, Ferrone S. 1999. HLA class I antigen downregulation in human cancers: T cell immunotherapy revives an old story. Mol Med Today 5:178-186.
39. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. 1997. Characterization of an antigen that is recognized on a melanoma exhibiting partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199-208.
40. Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, García A, Ruiz-Cabello F, Garrido F. 1999. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91-97.
41. Johnsen A, Templeton DJ, Sy MS, Harding CV. 1999. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 163:4224-4231.
42. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karback J, Jäger D, Oesch F, Knuth A. 1997. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142- 147.
43. Kaklamanis L, Hill A. 1992. MHC loss in colorectal tumours: Evidence for immunoselection. Cancer Surv 13:155-171.
44. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Scheriber RD. 1998. Demonstration of an interferon gamma dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556-7561.
45. Klein G, Sjögren HO, Klein E, Hellström KE. 1960. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autocthonous host. Cancer Res 20:1561-1572.
46. Koopman JO, Hammerling GJ, Moburg F. 1997. Generation, intracellular transport, and loading of peptides associated with MHC class I molecules. Curr Opin Immunol 9:80-88.
47. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. 2000. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 20:961-976.
48. Le Bouteiller P. 1994. HLA class I chromosomal region, genes, and products: Facts and questions. Crit Rev Immunol 14:89-129.
49. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patients are consistent with immune selection. Eur J Immunol 25: 340-347.
50. Ljunggren HG, Kärre K. 1990. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 11:237-244.
51. Lopez-Botet M, Llano M, Navarro F, Bellon T. 2000. Nk cell recognition of non-classical HLA class I molecules. Semin Immunol 12:109-119.
52. Maffei A, Papadopoulos K, Harris PE. 1997. MHC class I antigen processing pathways. Hum Immunol 54:91-103.
53. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. 2002. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: High frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51(7);389-396.
54. Mareel M, van Roy FM, de Baetseiller P. 1990. The invasive phenotypes. Cancer Metastasis Rev 9:45-62.
55. Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Geraghty DE, Garrido F. 2003. Analysis of HLA-E in human tumours. Immunogenetics 54(11):767-775.
56. Marincola MFM, Jaffe EM, Hicklin DJ, Ferrone S. 2000. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 74:181-273.
57. Mendez R, Serrano A, Jaeger E, Maleno I, Ruiz-Cabello F, Knuth A, Garrido F. 2001. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens 257:508-519.
58. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. 1996. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14:619-648.
59. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96:2233-2238.
60. Parham P, Ohta T. 1996. Population biology of antigen presentation by MHC class I molecules. Science 272:67-74.
61. Parmer E, Cresswell P. 1998. Mechanisms of MHC class I restricted antigen processing. Annu Rev Immunol 16:323-358.
62. Pellegrino MA, Ferrone S, Reisfeld MA, Irie RF, Golub SH. 1977. Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer 40:36-41.
63. Peltenburg LT, Schrier PI. 1994. Transcriptional suppression of HLAB expression by c-Myc is mediated through the core promoter elements. Immunogenetics 40:54-61.
64. Perez M, Algarra I, Ljunggren HG, Caballero A, Mialdea MJ, Gaforio JJ, Garrido F. 1990. A weakly tumorigenic phenotype with high MHC class I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma. Int J Cancer 46:258-261.
65. 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569-572.
66. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, López-Nevot MA, Garrido F. 2000. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001-1012.
67. Real LM, Cabrera T, Canton J, Kirkin AF, Garcia A, Abril E, Zeuthen J, Ruiz-Cabello F, Garrido F. 1998. In vivo and in vitro generation of a new altered HLA phenotype in melanoma tumor cell variants expressing a single HLA class I allele. Int J Cancer 75:317-323.
68. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. 2001. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19(6):1211-1220.
69. Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, Revel M. 1983. The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 2:239-243.
70. Rosenberg SA, Bennink JR. 1993. Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272.
71. Ruiz Cabello F, Garrido F. 1998. HLA and cancer: From research to clinical impact. Immunol Today 19:539-542.
72. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simona JW. 1995. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87(4):280-285.
73. Seliger B, Maurer MJ, Ferrone S. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455-464.
74. Seliger B, Cabrera T, Garrido F, Ferrone S. 2002. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3-13.
75. Serrano A, Brady CS, Jimenez P, Duggan-Keen MF, Mendez R, Stern PL, Garrido F, Ruiz-cabello F. 2000. A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics 51(12):1047-1052.
76. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F. 2001. Re-xpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94(2):243-251.
77. Seymour K, Pettit S, O'Flaherty E, Charnley RM, Kirby JA. 1999. Selection of metastatic tumor phenotypes by host immune system. Lancet 353:1989-1991.
78. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Scheriber RD. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 26:1107-1111.
79. Soong TW, Hui KM. 1992. Locus-specific transcriptional control of HLA genes. J Immunol 149:2008-2020.
80. Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. 1996. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 26:1844-1850.
81. Thomas L. 1959. Discussion of cellular and humoral aspects of the hypersensitivity states. In: Lawrence HS, editor. New York: Hoeber-Harper. pp 529-532.
82. Tomlinson I, Bodmer W. 1999. Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nat Med 5: 11-12.
83. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX, Garrido F. 1996. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 47:372-381.
84. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 28:959-968.
85. Trowsdale J. 2001. Genetic and functional relationships between MHC and NK receptor genes. Immunity 15(3):363-374.
86. Van Endert P. 1999. Genes regulating MHC class I processing of antigen. Curr Opin Immunol 11:82-88.
87. Villunger A, Strasser A. 1999. The great escape: Is evasion required for tumour progression? Nat Med 5:874-875.
88. Vitale M, Zimmer J, Castriconi R, Hanau D, Donato L, Bottino C, Moretta L, de la Salle H, Moretta A. 2002. Analysis of natural killer cells in TAP2-deficient patients: Expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood 1: 1723-1729.
89. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S. 1999. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 190:205-215.